Genomic Health (NASDAQ:GHDX) Rating Lowered to Hold at ValuEngine

Genomic Health (NASDAQ:GHDX) was downgraded by stock analysts at ValuEngine from a “buy” rating to a “hold” rating in a report released on Tuesday, ValuEngine reports.

A number of other equities analysts have also recently issued reports on the stock. Piper Jaffray Companies cut shares of Genomic Health from an “overweight” rating to a “neutral” rating in a research note on Monday, July 29th. BidaskClub upgraded Genomic Health from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, August 6th. Needham & Company LLC lowered Genomic Health from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 30th. JPMorgan Chase & Co. upgraded Genomic Health from an “underweight” rating to a “neutral” rating and raised their price target for the stock from $60.00 to $72.00 in a research report on Monday, July 29th. Finally, Deutsche Bank reduced their price target on Genomic Health from $80.00 to $55.00 and set a “hold” rating on the stock in a research report on Thursday, May 30th. Ten investment analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus price target of $69.86.

GHDX traded down $0.06 during mid-day trading on Tuesday, reaching $72.92. The stock had a trading volume of 6,579 shares, compared to its average volume of 557,530. The firm’s fifty day simple moving average is $73.17 and its two-hundred day simple moving average is $65.17. The stock has a market capitalization of $2.72 billion, a P/E ratio of 69.45 and a beta of 1.00. Genomic Health has a 52 week low of $50.77 and a 52 week high of $92.18. The company has a debt-to-equity ratio of 0.17, a quick ratio of 5.74 and a current ratio of 5.74.



Genomic Health (NASDAQ:GHDX) last posted its quarterly earnings results on Monday, July 29th. The medical research company reported $0.42 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.35 by $0.07. The business had revenue of $114.14 million for the quarter, compared to analysts’ expectations of $110.78 million. Genomic Health had a return on equity of 19.51% and a net margin of 11.69%. The firm’s quarterly revenue was up 19.4% compared to the same quarter last year. During the same quarter last year, the business earned $0.23 earnings per share. As a group, analysts expect that Genomic Health will post 1.51 EPS for the current fiscal year.

In other Genomic Health news, CEO Kimberly J. Popovits sold 25,000 shares of Genomic Health stock in a transaction dated Thursday, August 8th. The stock was sold at an average price of $73.85, for a total transaction of $1,846,250.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider James J. Vaughn sold 4,500 shares of Genomic Health stock in a transaction dated Monday, July 8th. The stock was sold at an average price of $57.09, for a total value of $256,905.00. The disclosure for this sale can be found here. Insiders have sold a total of 404,788 shares of company stock worth $28,587,699 in the last three months. 31.30% of the stock is owned by insiders.

A number of hedge funds have recently bought and sold shares of the business. DekaBank Deutsche Girozentrale lifted its position in Genomic Health by 2.9% in the 2nd quarter. DekaBank Deutsche Girozentrale now owns 7,000 shares of the medical research company’s stock valued at $394,000 after acquiring an additional 200 shares in the last quarter. Ladenburg Thalmann Financial Services Inc. lifted its holdings in shares of Genomic Health by 12.7% in the second quarter. Ladenburg Thalmann Financial Services Inc. now owns 3,301 shares of the medical research company’s stock valued at $192,000 after purchasing an additional 372 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of Genomic Health by 29.8% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,923 shares of the medical research company’s stock valued at $112,000 after purchasing an additional 441 shares in the last quarter. LPL Financial LLC lifted its holdings in shares of Genomic Health by 11.1% in the second quarter. LPL Financial LLC now owns 4,820 shares of the medical research company’s stock valued at $280,000 after purchasing an additional 483 shares in the last quarter. Finally, Northwestern Mutual Wealth Management Co. lifted its holdings in shares of Genomic Health by 166.0% in the first quarter. Northwestern Mutual Wealth Management Co. now owns 790 shares of the medical research company’s stock valued at $55,000 after purchasing an additional 493 shares in the last quarter. Hedge funds and other institutional investors own 95.36% of the company’s stock.

About Genomic Health

Genomic Health, Inc, a healthcare company, provides clinically actionable genomic information to personalize cancer treatment decisions in the United States and internationally. The company develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, which allows physicians and patients to make individualized treatment decisions.

Featured Article: The primary rules of Elliott Wave theory

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Genomic Health (NASDAQ:GHDX)

Receive News & Ratings for Genomic Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health and related companies with MarketBeat.com's FREE daily email newsletter.